AllSci News
Eli Lilly posts first data from Verve acquired in vivo base editor in hypercholesterolemia trial
Eli Lilly (NYSE: LLY) reported Phase Ib data from the Heart-2 trial showing that a single infusion of VERVE-102, an in vivo PCSK9 base editor, reduced LDL...
Regeneron files Otarmeni gene therapy for EU approval in genetic hearing loss
Regeneron Pharmaceuticals (Nasdaq: REGN) has received acceptance from the European Medicines Agency for a Marketing Authorization Application for Otarmeni...
HanchorBio moving towards circa USD 140m Taiwan Innovation Board listing
HanchorBio Inc. (TPEx: 7827), a Taiwan-headquartered clinical-stage immunotherapy company with offices in Shanghai and the San Francisco Bay Area, priced...
Novartis trying out mystery drug candidate for atopic dermatitis
An unidentified sponsor has registered a first-in-human trial of DCY636, an investigational drug whose molecular target has not been publicly disclosed, in...
China Medical System's TYK2 inhibitor picks up China trial nod for ulcerative colitis and Crohn's disease
China Medical System Holdings [HKEX: 0867], headquartered in Hong Kong, has received clinical trial approval from China's National Medical Products...
Kelun, Merck's sac-TMT plus Keytruda cuts progression risk by 65% in advanced NSCLC
Kelun-Biotech (6990.HK) is presenting Phase III data at ASCO 2026 showing that sacituzumab tirumotecan combined with Merck's Keytruda (pembrolizumab) cut...
Henlius Bio readies first-in-class EGFR/c-MET bispecific ADC for Phase I in China
Shanghai Henlius Biotech (HKEX: 2696) announced on May 21, 2026 that China's National Medical Products Administration has approved the investigational new...
Henlius advances STEAP1/CD3/ CD28 trispecific T-cell engager to Phase I in prostate cancer
Shanghai Henlius Biotech (HKEX: 2696) has received clearance to initiate a Phase I clinical trial of HLX3902, a trispecific T-cell engager antibody...
Lundbeck receives South Korean approval for Vyepti for preventive migraine treatment in adults
H. Lundbeck A/S has received marketing authorization from South Korea’s Ministry of Food and Drug Safety (MFDS) for Vyepti (eptinezumab; ALD403) for…
FDA grants accelerated approval to Gilead’s Hepcludex for chronic hepatitis delta virus infection
Gilead Sciences (Nasdaq: GILD) has received US FDA accelerated approval for Hepcludex (bulevirtide-gmod) for the treatment of chronic hepatitis delta virus (HDV)…
Shanghai Henlius puts B7H3 bifunctional fusion protein into Phase I testing for advanced solid tumours
Shanghai Henlius Biotech (HKEX: 2696) dosed the first patient in the HLX316 clinical trial, a Phase I first-in-human study evaluating the B7-H3-targeting...
TreeFrog posts preclinical data for 3D neural microtissue therapy in Parkinson's disease
TreeFrog Therapeutics, a Bordeaux-based regenerative medicine biotech, reported preclinical data on TFG-001, its 3D neural microtissue cell therapy for...
FDA expands Daiichi/AZ’s TROP2 ADC Datroway into first-line metastatic TNBC
The US FDA has approved Datroway (datopotamab deruxtecan-dlnk), a TROP2-directed antibody-drug conjugate co-developed by Daiichi Sankyo and AstraZeneca, for adult patients with…
Agios secures Euro approval for Pyrukynd in thalassemia
Agios Pharmaceuticals (Nasdaq: AGIO) has received European Commission marketing authorization for Pyrukynd (mitapivat) in adults with anemia associated with transfusion-dependent and non-transfusion-dependent…
EMA recommends Novo Nordisk’s Wegovy pill for obesity
Novo Nordisk’s Wegovy pill (oral semaglutide 25 mg) has received a positive opinion from the European Medicines Agency’s Committee for Medicinal Products…
The AllSci Brief
Systematic R&D and deal news. Daily.